MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Teva Pharmaceutical Industries Ltd Company Profile (NYSE:TEVA)

Consensus Ratings for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (?)
Ratings Breakdown: 5 Hold Rating(s), 20 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $71.29 (43.82% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetActions
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Citigroup Inc.Reiterated RatingBuy$75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016OppenheimerReiterated RatingBuy$77.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016MizuhoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Piper JaffrayReiterated RatingHold$58.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Credit SuisseReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Leerink SwannReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Jefferies GroupReiterated RatingBuy$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016RBC CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Deutsche BankLower Price TargetBuy$80.00 -> $71.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Maxim GroupLower Price TargetBuy$74.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Morgan StanleyReiterated RatingOverweight$71.00 -> $69.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Goldman SachsReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016GuggenheimReiterated RatingBuy$80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Bank of AmericaReiterated RatingBuy$82.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016BTIG ResearchReiterated RatingBuy$77.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016HSBCReiterated RatingHold$63.00 -> $61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Sanford C. BernsteinReiterated RatingOutperform$43.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016NomuraReiterated RatingNeutral$73.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/21/2016ArgusReiterated RatingBuy$82.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/28/2015BMO Capital MarketsUpgradeMarket Perform -> Outperform$75.00 -> $80.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2015Standpoint ResearchBoost Price TargetBuy$78.00 -> $84.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2015Raymond JamesInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2015Cowen and CompanyReiterated RatingOutperform$100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/24/2015GabelliReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2015BarclaysBoost Price TargetOverweight$70.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2015CRT CapitalBoost Price TargetBuy$67.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/20/2015Sterne Agee CRTSet Price TargetBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2014ING GroupInitiated CoveragePositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Evercore ISIInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012$1.28$1.28ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2012$1.44$1.47ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/15/2012$1.58$1.59ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011$1.22$1.25ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2011$1.08$1.10ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2011$1.03$1.04ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2011$1.28$1.25ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
No earnings estimates for this company have been tracked by MarketBeat.com

Current Dividend Information for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Annual Dividend:$1.16
Dividend Yield:2.34%
Payout Ratio:22.70%
Dividend Growth:13.00% (3 Year Average)

Dividend History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016Tweet This Announcement  Share This Announcement on StockTwits
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015Tweet This Announcement  Share This Announcement on StockTwits
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014Tweet This Announcement  Share This Announcement on StockTwits
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014Tweet This Announcement  Share This Announcement on StockTwits
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014$0.342/20/20142/24/20143/10/2014Tweet This Announcement  Share This Announcement on StockTwits
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013Tweet This Announcement  Share This Announcement on StockTwits
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013quarterly$0.328/20/20139/2/2013Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013Tweet This Announcement  Share This Announcement on StockTwits
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateHeadline
06/28/16 06:38 PMWho's Buying Teva Pharmaceutical Industries Ltd (NYSE:TEVA) US Assets? - Market Exclusive
06/28/16 06:38 PMMayne Pharma Acquiring 42 Generic Drugs
06/28/16 06:38 PMTeva Pharmaceutical : and Antares Pharma Announce Launch of Generic Imitrex in the United States
06/28/16 04:35 PMTeva Inches Closer to Completion of Allergan Generics Deal -
06/28/16 03:10 PMWhy Teva Pharma Continues to Sell Assets (TEVA) -
06/28/16 09:29 AMTeva Pharmaceutical Industries Limited (NYSE:TEVA) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 09:29 AMSkyline Medical Inc (NASDAQ:SKLN) & Teva Pharmaceutical Industries (NYSE:TEVA) Healthcare Notable Runners - Wall Street 24
06/28/16 09:29 AMHotspot Stocks in Hit List- Agilent Technologies (NYSE:A), Teva Pharmaceutical Industries (NYSE:TEVA), MeetMe ... - Seneca Globe
06/28/16 09:29 AMHC Stocks in Top Row: Novavax, Inc. (NASDAQ:NVAX), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) - share market updates (press release)
06/28/16 09:29 AMFDA accepts Teva's NDAs for two asthma candidates - Seeking Alpha
06/28/16 09:29 AMAnalysts Update on Stocks: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Alexion Pharmaceuticals, Inc ... - Street Updates
06/28/16 09:28 AMBRIEF-Prasco acquires Teva's generic of Adderall XR extended release capsules, CII
06/28/16 09:28 AMTeva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate RespiClick ® Inhalers
06/27/16 06:37 PMShare Update and Earnings Review for Teva Pharmaceutical Industries Limited (NYSE:TEVA) - Press Telegraph
06/27/16 06:37 PMCovering the Bases on Teva Pharmaceutical Industries Limited (NYSE:TEVA): Where is the Stock Going? - Press Telegraph
06/27/16 06:37 PMMayne Pharma nears deal for Teva assets
06/27/16 09:03 AMShort Sellers Increase Bets Against Major Pharmaceutical Stocks
06/27/16 09:03 AMTeva Pharmaceutical : and Antares Pharma Announce Launch of Generic Imitrex® in the United States
06/27/16 09:03 AMTeva and Antares Pharma Announce Launch of Generic Imitrex® in the United States
06/27/16 09:03 AMTeva Pharmaceutical Industries Ltd (NYSE:TEVA) Is Keeping Its Fingers Crossed on CINQAERO
06/27/16 09:03 AMRecommendation Trends for: Teva Pharmaceutical Industries Limited (NYSE:TEVA) - News Oracle
06/27/16 09:03 AMTeva Pharmaceutical Industries Ltd (NYSE:TEVA) Is Keeping Its Fingers Crossed on CINQAERO - Market Exclusive
06/27/16 08:21 AMTEVA and Antares Pharma Announce Launch of Generic Imitrex in the United States - [at noodls] - a1256214-1441-4852-a4ba-d1f936a0eb05.pdf TEVA AND ANTARES PHARMA ANNOUNCE LAUNCH OF GENERIC IMITREX® IN THE UNITED STATES Jerusalem and Ewing, NJ, June 23, 2016 - Teva Pharmaceutical Industries Ltd., (NYSE ...
06/26/16 09:15 AMTop Gainers of the Day: Teva Pharmaceutical Industries Limited (NYSE:TEVA) from Drug Manufacturers – Other - Twin County News
06/25/16 10:24 AMTeva Pharma (TEVA) Receives Positive CHMP Opinion on CINQAERO
06/24/16 06:48 PMTeva Pharmaceutical Industries Limited (NYSE:TEVA) Analyst Rating Consensus - Trade Calls
06/24/16 06:48 PMA Prescription For Teva Shareholders On Actavis Generics - Seeking Alpha
06/24/16 09:19 AMTeva Pharmaceutical Industries Limited (NYSE:TEVA) Boasts Rating Of 1.53 - Stocks Daily
06/24/16 09:19 AMTeva Gets CHMP Positive Opinion For CINQAERO - Quick Facts
06/24/16 09:19 AMTeva Pharmaceutical : Receives CHMP Positive Opinion for CINQAERO® (reslizumab)
06/24/16 09:19 AMTeva Receives CHMP Positive Opinion for CINQAERO® (reslizumab)
06/24/16 08:37 AMTeva Gets Positive Opinion For Its CINQAERO From EU's CHMP - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) revealed that it received a positive opinion from European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for its CINQAERO. The drug is a humanized interleukin 5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment. Teva Global Specialty Medicines President and CEO, Rob Koremans, commented, "As a company committed to providing medicines and solutions for people around the world living with respiratory disease, Teva ...Full story available on Benzinga.com
06/24/16 08:12 AMAllergan (AGN) Gets FDA Nod for Avycaz Label Expansion -
06/23/16 07:30 PMAnalyst's Stocks Ratings Trend: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , GlaxoSmithKline PLC (NYSE ... - Street Updates
06/23/16 12:07 PMAstraZeneca, Teva Resolve Their Patent Row Over Diabetes Product -
06/23/16 09:21 AMStocks to Track: Energy Transfer Equity LP (NYSE:ETE), Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) - NYSE Journal (press release)
06/23/16 09:21 AMHC Stocks in the Rumor: Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Opko Health Inc. (NYSE:OPK) - share market updates (press release)
06/23/16 09:00 AMTeva, AstraZeneca settle patent dispute over multimillion-dollar drug -
06/23/16 07:32 AM8:32 am Teva Pharma settles patent litigation with AstraZeneca (AZN); Teva gains right to commercialize generic version of BYETTA in the U.S. beginning October 15, 2017 -
06/23/16 07:30 AMTeva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta® (Exenatide Injection) in the United States - [Business Wire] - Teva Pharmaceuticals USA, Inc., today announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC relating to AstraZeneca’s US Patent Nos.
06/22/16 09:08 AMImpax (IPXL) Stock Declines on Deal to Buy Generic Products
06/22/16 09:08 AMImpax to Buy Allergan, Teva Drug Portfolio for $586 Million
06/22/16 09:08 AMSkyline Medical Inc (NASDAQ:SKLN) & Teva Pharmaceutical Industries (NYSE:TEVA) Healthcare Stocks Intraday Alert - Wall Street 24
06/21/16 06:15 PMCadila Healthcare : Zydus Cadila to acquire two ANDAs from Teva Pharmaceutical Industries
06/21/16 06:15 PMImpax to Buy Allergan, Teva Drug Portfolio for $586 Million (2)
06/21/16 06:15 PMOverview of Analyst's Recommendations: Teva Pharmaceutical Industries Limited (NYSE:TEVA) , Horizon Pharma plc ... - Street Updates
06/21/16 04:35 PMImpax Buys Mystery Generics Portfolio From Teva, Allergan -
06/21/16 08:55 AMImpax buys generic drugs from Teva, Allergan for $586 mln
06/21/16 08:55 AMTeva and Allergan Sell Generic Drugs to Impax In Latest Divestiture
06/21/16 08:55 AMTeva Pharmaceutical Industries Limited (NYSE:TEVA): Updated Analyst Ratings
About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd logoTeva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: TEVA
  • CUSIP:
Key Metrics:
  • Previous Close: $49.57
  • 50 Day Moving Average: $52.05
  • 200 Day Moving Average: $57.02
  • P/E Ratio: 25.70
  • P/E Growth: 1.77
  • Market Cap: $45.31B
  • Current Quarter EPS Consensus Estimate: $5.25 EPS
Additional Links:
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha